Hansa Biopharma AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr1,437.5 Mil.
Hansa Biopharma AB's quarterly Total Liabilities
declined
from Sep. 2025 (kr1,301.85 Mil) to Dec. 2025 (kr1,255.76 Mil) but then
increased
from Dec. 2025 (kr1,255.76 Mil) to Mar. 2026 (kr1,437.46 Mil).
Hansa Biopharma AB's annual Total Liabilities
increased
from Dec. 2023 (kr1,185.92 Mil) to Dec. 2024 (kr1,390.48 Mil) but then
declined
from Dec. 2024 (kr1,390.48 Mil) to Dec. 2025 (kr1,255.76 Mil).
Hansa Biopharma AB Total Liabilities Related Terms
Hansa Biopharma AB Total Liabilities Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Hansa Biopharma AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of kr1,437.5 Mil mean?
Hansa Biopharma AB (OSTO:HNSA) has a Total Liabilities of kr1,437.5 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Total Liabilities too high?
Hansa Biopharma AB's current Total Liabilities is kr1,437.5 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Total Liabilities compare to VRTX and REGN?
Hansa Biopharma AB's Total Liabilities of kr1,437.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Total Liabilities is kr1,437.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.48, compared to a current price of kr34.80 — trading 42.2% above its estimated fair value. The current Total Liabilities is kr1,437.5 Mil. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Total Liabilities is kr1,437.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr34.80 is trading 42.2% above its estimated GF Value™ of kr24.48.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
Total Liabilities: kr1,437.5 Mil
GF Value™: kr24.48 vs. price of kr34.80 (42.2% above fair value)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for OSTO:HNSA
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
